Latest Us Market News

SelfWealth Limited reported a modest revenue increase for the half-year ended December 2024, yet profits plunged sharply due to higher operating expenses as the company prepares for a potential acquisition by Bell Financial Group.

Cyclopharm has inked a pivotal three-year agreement with HCA Healthcare, enabling deployment of its Technegas® lung imaging technology across up to 169 US nuclear medicine departments. This deal marks a major step in expanding Technegas®’ footprint in the American healthcare market.

Archer Materials has been granted a pivotal US patent for its Biochip technology, safeguarding its intellectual property and positioning the company for strategic entry into the lucrative US medical diagnostics market.

Compumedics has locked in a pivotal five-year contract with Philips Australia, cementing Somfit as the leading device for pharmacy-based sleep testing and underpinning significant SaaS revenue growth through 2028.

Bubs Australia has reported a strong Q2 FY25 performance with a positive EBITDA turnaround and robust revenue growth, while advancing its critical FDA clinical trial in the US.

Respiri Limited has completed its acquisition of Orb Health Inc. for US$9 million in shares, marking a strategic move to strengthen its foothold in the US connected and chronic care market. The integration promises operational cost savings and expanded service offerings.

Immuron Limited reports a striking 70% quarter-on-quarter increase in Travelan® sales, driven by expanded pharmacy distribution in Australia and North America.

Orthocell Limited has reported a third consecutive quarter of record revenue, driven by strong sales growth and strategic market expansions, including a key US FDA submission for its nerve repair product Remplir™.

Pacific Edge faces a significant Medicare reimbursement setback as Novitas finalizes a non-coverage decision for its Cxbladder tests, prompting the company to activate legal challenges and operational restructuring.